-

Rapid Medical Announces the Addition of Daniel Levangie to Its Board of Directors

The company continues to expand its global business, launching multiple products in the United States and internationally in 2021

YOKNEAM, Israel--(BUSINESS WIRE)--Rapid Medical, a company focused on the development of responsive, adjustable neurovascular devices, announced today that Daniel Levangie has been appointed to its Board of Directors.

“We are thrilled to welcome Dan. Dan brings vast commercial experience, a deep perspective, and proven capabilities to our Board of Directors. His expertise will be invaluable and will complement the skills of our existing board members as we continue to grow and scale our company. I look forward to working with Dan,” said Dr. Shimon Eckhouse, the Chairman of Rapid Medical’s board.

Mr. Levangie is the Chairman, CEO and co-founder of Cerevasc, Inc., as well as the co-founder and Managing Partner of ATON Partners. In addition, he is a member of the Board of Directors of Exact Sciences, Inc. and Renovia, Inc. His long-term interest in the stroke treatment market started during his tenure as the Chairman of ev3 prior to its acquisition by Covidien.

"I am excited to join such a dynamic and mission-driven company," said Dan. "Rapid Medical’s technology is a game-changer in neurovascular intervention. Through its innovative technology, its devices are fully adjustable in the brain. This means the devices are equipped to handle a broader range of patient anatomies and situations. I am looking forward to the opportunity to build a strong business with a significant impact on the lives of stroke patients."

About Rapid Medical

Rapid Medical develops premier responsive interventional devices for endovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER™ 17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER™ 13 and XL are also CE marked. More information is available at www.rapid-medical.com.

Contacts

Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com

Rapid Medical


Release Summary
Rapid Medical announces the addition of Daniel Levangie to its Board of Directors as the company continues to expand its global business.

Contacts

Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com

Social Media Profiles
More News From Rapid Medical

Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions

SOUTHLAKE, Texas & YOKNEAM, Israel--(BUSINESS WIRE)--Rapid Medical completes DISTALS enrollment for TIGERTRIEVER 13 for DMVO stroke, backed by interim safety data and demand for distal-specific devices....

Rapid Medical™ Appoints Industry Veteran Nir Nimrodi to Its Board of Directors

SOUTHLAKE, Texas & YOKNEAM, Israel--(BUSINESS WIRE)--Rapid Medical adds Nir Nimrodi to Board, fueling global expansion and breakthroughs in neuro intervention and stroke treatment.....

Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval

SOUTHLAKE, Texas & MARSEILLE, France--(BUSINESS WIRE)--Clinical success and MDR approval position DRIVEWIRE™ 24 as a next-generation access technology set to reshape neurovascular practice....
Back to Newsroom